THERAPIES FOR CHRONIC MYELOID LEUKAEMIA
Professor Tim Hughes
Clinical Director Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI)
& Consultant Haematologist, Royal Adelaide Hospital, South Australia
RESEARCHER PROFILE (Filmed in Adelaide, South Australia | December 2024)
Professor Tim Hughes is the Chronic Myeloid Leukaemia Group Leader at SAHMRI, Clinical Director in the Precision Cancer Medicine Theme at SAHMRI and Consultant Haematologist in the Division of Haematology at SA Pathology and at the Royal Adelaide Hospital.
He is also Inaugural Fellow of the Australian Academy of Health and Medical Sciences (AAHMS) and Fellow of the Australian Academy of Science.
Professor Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 350 papers that have been cited over 65,000 times.
He has been recognised for his achievements with several national awards including the GSK Award for Research Excellence in 2017 for pioneering the use of tyrosine kinase inhibitors (TKIs) and the Ramaciotti Medal for Excellence in Biomedical Research in 2019. He was also awarded the International CML Foundation Goldman Prize in 2017 for lifetime contributions to improving outcomes for patients with CML.
-
Vision impairment in children and the impact on children and their families
Dr Sue Silveira holds a conjoint academic position with Macquarie University and is the Course Director for their Master of Disability Studies, which is administered and delivered by NextSense Institute in affiliation with the University. She teaches in the areas of vision impairment and disability, and aims to share her knowledge while learning from others, especially people who are blind or have low vision and their families.
-
Metabolic phenotyping, lipidomics & bioinformatics in dementia
Dr Luke Whiley is a dementia researcher whose work focuses on understanding how the body’s metabolism, particularly the biology of fats known as lipids, influences our health throughout ageing.
His research explores how the body responds to illness, lifestyle, and environmental stress at a chemical level, and how these responses shape longterm disease risk. Using advanced blood-based measurement technologies, Dr Whiley studies thousands of small molecules at once to build a snapshot of a person’s metabolic health. By combining these measurements with data science approaches, his work identifies biological pathways that become disrupted in disease, providing insight into why some people are more vulnerable to conditions such as dementia.
-
Genetics and Environmental Factors of Glaucoma & Myopia
Professor David Mackey’s original research, over more than 30 years into the genetics of glaucoma and in the fields of optic atrophy and congenital cataract, has received constant professional accolades, attracted ongoing research funding and led to his publication of more than 400 peer-reviewed papers.
